{"id":1016987,"date":"2026-11-05T02:46:25","date_gmt":"2026-11-05T07:46:25","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-reports-third-quarter-2026-financial-results-and-provides-business-update\/"},"modified":"2026-11-05T02:46:25","modified_gmt":"2026-11-05T07:46:25","slug":"cytokinetics-reports-third-quarter-2026-financial-results-and-provides-business-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-reports-third-quarter-2026-financial-results-and-provides-business-update\/","title":{"rendered":"Cytokinetics Reports Third Quarter 2026 Financial Results and Provides Business Update"},"content":{"rendered":"
\n

\n MYQORZO<\/em>
\n
\n \u00ae<\/em>
\n <\/sup>
\n (aficamten) Net Product Revenue of $44.5 Million<\/em>\n <\/p>\n

\n Expect to Submit Supplemental NDA for Aficamten in Non-Obstructive HCM in Q4 2026 and Type II Variation in the European Union in Early 2027<\/em>\n <\/p>\n

\n ~$1.6 Billion in Cash, Cash Equivalents and Investments as of September 30, 2026<\/em>\n <\/p>\n

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) reported a management update and financial results for the third quarter of 2026.<\/p>\n

\u201cOur third quarter results demonstrate continued strong execution as Cytokinetics enters its next phase of growth as a global specialty cardiology biopharmaceutical company,\u201d said Robert I. Blum, Cytokinetics\u2019 President and Chief Executive Officer. \u201cIn the U.S., the launch of MYQORZO continued to build solid momentum and increased velocity with growing adoption across a broadening base of prescribers. Internationally, we continued to expand access to MYQORZO to bring this important medicine to more patients around the world. Now, with our having presented and published the primary results from ACACIA-HCM, the first positive Phase 3 clinical trial in nHCM, we believe aficamten <\/em>has the potential to become the first and only cardiac myosin inhibitor approved across the full spectrum of HCM. Building on these key results, we are moving swiftly to seek regulatory approvals in both the U.S. and Europe, important next steps toward achieving our Vision 2030.\u201d<\/p>\n

\n Q3 and Recent Highlights <\/strong>\n <\/p>\n

\n
\n Cardiac Muscle Programs<\/u>
\n <\/strong>\n <\/p>\n

\n MYQORZO<\/strong>
\n
\n \u00ae<\/strong>
\n <\/sup>
\n (<\/strong>
\n
\n aficamten<\/em>
\n <\/strong>
\n )<\/strong> (cardiac myosin inhibitor)<\/p>\n